German company CureVac and Eli Lilly and Co. will collaborate on developing up to five mRNA cancer vaccines using CureVac's RNActive technology, with Lilly determining the diseases to be targeted, conducting clinical studies and marketing any FDA-approved vaccines. Lilly will pay CureVac $50 million in cash upfront plus up to $1.7 billion in milestones and will also invest about $53.1 million in the company, granting Lilly an approximate 3% share in the biotech firm.
Partnership to advance mRNA cancer vaccine development for 5 targets
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.